Simple and complex retroviral vectors derived from Moloney murine leukemia virus (MLV) and human immunodeficiency virus type 1 (HIV-1), respectively, are useful tools for gene transfer studies. However, factors affecting the stability of these vectors have not been carefully investigated. Here we studied the stability factors on vesicular stomatitis viral envelope glycoprotein (VSV-G)-pseudotyped MLV-and HIV-1-derived vectors. Analysis of the ratio of defective particles versus infectious units using electron microscopy and a functional transduction assay revealed that both vectors consisted of high numbers of defective particles (ϳ100-350:1), which could be reduced (ϳ10-20:1) by centrifugation. Frequent freeze-andthaw rapidly decreased vector titer in the first three to five cycles and stabilized thereafter. Both viral vectors were sensitive to temperatures above 37°C but more stable at temperatures below 37°C, exhibiting a two-phase inactivation kinetic starting with a steep inactivation phase, followed by a more leveled phase. Interestingly, HIV-1-derived vectors were significantly more stable than MLV-derived vectors at higher temperatures (Ͼ37°C). Both vectors were rapidly destabilized at pH either below or above 7.0. Incubation with human or mouse serum significantly inhibited VSV-G-pseudotyped vector activities. Preheated human serum still reduced vector half-lives to ϳ50% (150 min), suggesting that certain inactivation factors are not heat-labile. Analyses of these stability factors may improve future production and applications of retroviral and lentiviral vectors.
INTRODUCTION
Viral vectors are useful tools for gene delivery. Retroviral vectors require Gag-Pol and Env proteins to be coexpressed for particle assembly. The transgene of interest is constructed on a separate vector which, upon infection, randomly integrates into host cell chromosome. These features of integration and potential longterm transgene expression make the retroviral vector a popular gene transfer tool for laboratory and clinical use (Miller et al., 1993) . Although integration is a necessary step in the retroviral life cycle, for simple retroviruses such as MLV, this process requires cell division coupled with a breakdown of nuclear membranes, to allow nuclear translocation of the proviral integration complexes. On the other hand, lentiviral vectors infect both dividing and nondividing cells and therefore could potentially overcome the shortcoming of the limited target range of conventional retroviral vectors.
The stability and pharmacokinetics of both retroviral and lentiviral vectors have not been well characterized; such information would be valuable for both in vitro and in vivo applications. Viral vector stability can be influenced by various factors, including temperature, pH, freeze-and-thaw frequency, and incubation conditions, including growth media and serum components during vector production and transportation.
The half-life of retroviral vectors in vivo correlates with their in vitro resistance to serum complement (DePolo et al., 1999) and the sensitivity of retroviral vectors to human serum is dependent on the species of producer cells (Cosset et al., 1995; Pensiero et al., 1996) . Retroviruses produced in murine cells have a very short half-life (Ͻ1 min) following intravenous administration in macaques (Cornetta et al., 1990) . Retroviral vectors produced from cells expressing galactosyl (␣1-3) galactosyl (␣Gal) are sensitive to human serum as a result of the activities of anti-␣Gal antibodies in human serum (Takeuchi et al., 1997; Welsh et al., 1998) . In addition to the producer cell type, the type of envelope protein can also influence complement sensitivity of MLV (Takeuchi et al., 1994) . For example, rapid inactivation may occur to those vectors expressing the xenotropic viral envelope, rather than to those expressing the amphotropic viral envelope (DePolo et al., 1999) . The HIV-1 and MLV vectors used in this study were pseudotyped with the VSV-G envelope and produced from TE671 cells, a human cell line which does not express ␣Gal.
We examined the physical properties and serum sensitivity of both lentiviral and retroviral vectors produced by two human producer cell lines (TE671 or 293). Vector stability was monitored by an infectivity assay following different pH, temperature, freeze-and-thaw, and mouse or human serum treatments. We also investigated the ratio of defective particle formation for both vector types. The information gathered from this study will be of general interest to preclinical and clinical researchers using these two vector systems.
RESULTS

Ratios of defective particle versus infectious units of retroviral and lentiviral vectors
Both retro-and lentiviruses produce defective particles during infections (Bernier and Tremblay, 1995; Huang and Baltimore, 1970; Meyerhans et al., 1989) . It is not clear, however, what percentages of viral particles produced by the vector-producer cells are defective following the DNA cotransfection protocol. In other words, the ratios of retroviral or lentiviral particles versus their infectious units have not been carefully examined. To investigate this, MLV-and HIV-1-derived vectors were prepared by DNA cotransfection in TE671 cells as previously described (Chang et al., 1999) . The VSV-Gpseudotyped viral vectors were concentrated by centrifugation and the titer of each vector was determined by ␤-galactosidase assay on TE671 cells. Both unconcentrated and concentrated virus preparations were examined by mixing different dilutions of the virus samples with a known concentration of 142-nm latex beads and counted under EM. Representative EM pictures of retroviral and lentiviral vector/bead mixtures are shown in Fig.  1 , and the particle versus infectious unit ratios are summarized in Table 1 . The ratios of particles to infectious units for MLV-and HIV-1-derived vectors were determined to be 117:1 and 346:1, respectively, for unconcentrated vector particles, and 7:1 and 18:1, respectively, for concentrated vector particles. It appears that HIV-1-derived lentiviral vectors have a higher ratio of defective particles than do MLV-derived retroviral vectors.
Biphasic freeze-and-thaw kinetics of retroviral and lentiviral vectors
To test the effects of frequent freeze-and-thaw on vector activity, both pseudotyped retro-and lentiviral vectors were subjected to multiple rounds of freeze-and-thaw treatment followed by titration on TE671 cells. The viral vectors were collected from culture supernatants and either used for infection directly or subjected to one round of concentration by microfuge centrifugation before infecting TE671 cells. The titers of both concentrated and unconcentrated virus samples were determined as described under Materials and Methods. The results are summarized in Fig. 2 . Interestingly, a biphasic infectivity kinetic was observed for both MLV and HIV-1 vectors, with two linear phases intercepted at the point between the third and the fifth freeze-and-thaw cycles. This biphasic kinetic is observed for both concentrated and unconcentrated vectors. The vector half-life was determined to be 3.8 and 11.8 freeze-and-thaw times for the first and the second phase, respectively, and was consistent for both virus types and for both the high and the low concentration of samples.
The temperature effects on VSV-G-pseudotyped retroviral and lentiviral vectors
To determine the temperature effects, retro-and lentiviral vectors were incubated at 4, 20, 37, 45, or Note. Viral particle number (upper row) and infectious units (titer) were quantified under EM and by a functional transduction assay on TE671 cells, respectively.
50°C for different periods of time and the vector titer was then determined as described above. The vector transduction efficiencies decreased rapidly with increasing temperature for both vector types (Fig. 3A) . Based on the transduction kinetics, both HIV and MLV are considerably unstable at room temperature with half-lives between 1 and 2 days (Fig. 3B) . The half-lives of both vectors were markedly decreased at temperatures above 4°C. At 37°C, the half-lives of HIV-1 and MLV vectors were 10.4 Ϯ 1.2 and 4.5 Ϯ 1.0 h, respectively (Fig. 3B) . Interestingly, the MLV vectors were significantly less stable than the HIV-1 vectors at higher temperature (i.e., 37, 45, and 50°C), whereas at low temperature (i.e., 4°C), the MLV vectors appeared to be more stable than the HIV-1 vectors (Fig. 3B ). To simulate a chemical reaction incorporating these conditions, we analyzed these data using the Arrhenius equation; this equation expresses a logarithmic relationship between the rate constant of the vector inactivation reaction and the reciprocal of the absolute temperature. An Arrhenius plot was composed using the ␤-phase rate constants of vector inactivation at 4, 20, and 37°C (Fig. 3C ). The result showed that both vectors were characterized by a break at 37°C, even though we chose the rate constants derived from the ␤-phase obtained at 4, 20, and 37°C. A steep slope in the Arrhenius plot means that the rate constant increases dramatically as the temperature increases. Therefore, the vector inactivation kinetics consisted of two inactivation energy values, 61.7 kcal/mol above 37°C and 12.7 kcal/mol below 37°C for HIV-1 vectors, and 62.9 kcal/mol above 37°C and 9.9 kcal/mol below 37°C for MLV vectors (Fig. 3C ).
The pH effects on vector stability
We further examined vector stability under different pH conditions at no ionic strength. The pH range tested was from 5.0 to 9.0. VSV-G-pseudotyped viral vectors were incubated in different pH buffers prepared as described under Materials and Methods. The pH was neutralized by dilution of the pH buffer, containing the virus, with a high volume of culture media. The results showed that both HIV-1 and MLV vectors were stable at pH 7.0, and gradually destabilized as the pH either increased or decreased (Fig. 4) . The half-lives of both viral vectors at pH 6.0 and pH 8.0 markedly dropped to less than 10 min.
Virus stability in human or mouse serum
To see whether vector stability could be affected by incubation with serum, concentrated MLV-and HIV-1-derived vectors were mixed with either mouse or human sera (heparin-treated) at a 1:1 ratio and incubated at 37°C for different periods of time, to determine their half-lives. Our preliminary studies indicated that the TE671 cells used for vector titer study are extremely sensitive to mouse serum treatment; we observed ϳ80% TE671 cell death after 24-h incubation with 1% of mouse serum and ϳ50% cell death after 3-h incubation with 5% of mouse serum. Likewise, we observed ϳ50% TE671 cell death following incubation with 10% unheated human serum. Such tissue culture serum sensitivity was less severe with HeLa cells. Therefore, this study was performed using HeLa cells as the target cells.
We compared the titers of both MLV and HIV vectors following human or mouse serum incubation at 37°C. The results showed that unheated mouse and human sera rapidly inactivated both viral vectors, with Ͼ50% inhibition of HIV vector activity by human serum and Ͼ90% inhibition of MLV vector activity by mouse serum, after a 30-min incubation (Fig. 5) . The serum effect on viral half-lives was further determined by incubation for different periods of time and the results are summarized in Table 2 . The half-lives of VSV-G-pseudotyped vectors, both MLV-and HIV-derived, were markedly decreased after incubation in unheated human or mouse sera. To determine whether this inhibitory effect could be eliminated by heat treatment, mouse and human sera were heated at 56°C for 30 min, which is a standard protocol for inactivating serum complement. As illustrated in Fig.  5 , both MLV and HIV vectors were less affected in heated human sera after 30-min incubation, with HIV vectors retaining Ͼ80% of baseline activity. To the contrary, both MLV and HIV vectors were inhibited to the same extents in heat-treated mouse sera as compared with incubation in unheated mouse sera for 30 min (Fig. 5) . This result suggests that the inhibitory factors present in the mouse serum are heat-resistant. To see whether such inhibitors were associated with B or T immune effector cells in   FIG. 2 . Freeze-and-thaw effect on retroviral and lentiviral vector titer. Unconcentrated (low concentration) and concentrated (high concentration) viral preparations were subjected to multiple freeze-and-thaw cycles as indicated and vector titer was determined by infecting TE671 cells and performing the ␤-galactosidase assay as described under Materials and Methods. The mean values of three independent experiments are used for the graph.
mice, we treated both HIV and MLV vectors with sera obtained from severe combined immunodeficiency mice (SCID) lacking both B-and T-cell functions. Compared with human and normal mouse serum treatment, the result showed that both HIV and MLV vectors recovered 30 and 80% activities, respectively, when treated with SCID mouse serum ( Table 2 ). In particular, MLV vector function was mostly preserved under SCID serum treatment.
DISCUSSION
In this study, we investigated retroviral and lentiviral vector stability by measuring vector transduction efficiency using TE671 or HeLa cells. Vector transduction efficiency was determined by an enzyme assay using the nuclear lacZ reporter gene. Through EM and titer studies, we showed that both vector systems produced high ratios of defective particles, higher than 99%, 117:1 for the retroviral vectors and 346:1 for the lentiviral vectors. It was previously reported that high percentages of defective HIV particles are produced from infected tissues of AIDS patients and by cell lines chronically infected with HIV-1 (Bernier and Tremblay, 1995; Meyerhans et al., 1989) . Our vector production protocols employ a DNA cotransfection method that could facilitate numerous recombination events. It is conceivable that the DNA cotransfection protocol produces more defective particles than established producer cell lines. Interestingly, such VSV-G-pseudotyped and defective viral particles could be markedly reduced (by 15-to 20-fold) after a simple centrifugation step. It appears that defective, low-density viral particles are largely eliminated through centrifugation.
We further investigated factors affecting the vector stability. The interruption of any viral replication steps during infection, from receptor binding to proviral integration, could lead to vector inactivation. Viral proteins such as the Gag matrix protein (MA), capsid p24 (CA), nucleocapsid p7 (NC), reverse transcriptase (RT), integrase (IN), or the pseudotyped viral envelope VSV-G could potentially be the target of inactivation. In freezeand-thaw experiments, two kinetic components were observed. Both HIV-1 and MLV were inactivated rapidly in the first phase followed by a stabilized phase after five freeze-and-thaw cycles. Because we determined vector inactivation by functional transduction assay, the observed biphasic kinetics could be explained by any of the following two possibilities: (1) there were two populations of vector particles, one of which was more fragile than the other, and (2) each viral particle contained two different degradation sites or components, again, one component of which was more fragile than the other. It was previously reported that binding of the HIV envelope glycoprotein (gp160) to CD4 was decreased by 50% after two freeze-and-thaw cycles but was not further affected by subsequent freeze-and-thaw up to 15 cycles (Papandreou et al., 1996) . This is consistent with our observation, although in our study the VSV-G envelope was used as a pseudotype envelope.
The study of the temperature effects showed that MLV vectors were less stable than HIV-1 vectors at temperatures higher than 37°C, and both vectors displayed a biphasic inactivation kinetic. The Arrhenius plot analysis   FIG. 4 . The pH effect on vector stability. Retroviral and lentiviral vectors were incubated under different pH conditions at 37°C for different lengths of time (from 5 to 120 min) and subsequently used to infect TE671 cells for titer determination. Phosphate buffer was used for pH 5-7 and Tris-HCl buffer for pH 7-9, as described under Materials and Methods. The titer value at pH 7 was presented as the average of both buffer systems. The half-lives of both vectors are plotted against different pH conditions. Mean values Ϯ SE of three to five trials are presented. using inactivation constants of the second phase (␤-phase) of the temperature incubation kinetics suggests that there is a breaking point at or around 37°C. This type of biphasic plot again implies that at least two components with different inactivation kinetics are affected by the treatment.
Compared with adenovirus and adeno-associated virus (Johnson and Bodily, 1975) , both the HIV-1 and MLV vectors are sensitive to the pH variations, in that the inactivation rates changed dramatically under nonphysiological pH conditions. Interestingly, a recent study reports that a decrease in pH reduces adenovirus vector titer during dry-ice shipment (Nyberg-Hoffman and Aguilar-Cordova, 1999). Thus, the storage and shipment of HIV-1 and MLV vectors should also consider pH variations.
We also observed that both retroviral and lentiviral vectors pseudotyped with VSV-G envelope were quite unstable in human or mouse sera. In general, the HIV-1 vector was less stable than the MLV vector in human serum, whereas the MLV vector was less stable than the HIV-1 vector in mouse serum. The half-life of the VSV-Gpseudotyped lentiviral vector was about 25 min in medium containing 50% unheated human serum. Antibody neutralization of virus particles is a common mechanism of host defense. Thus, this serum inactivation effect could be entirely attributed to the VSV-G-pseudotyped envelope used in this study. VSV is a mouse pathogen and is widespread in the western swine population, but its association with humans is not well characterized (Rodriguez et al., 2000) . TE671-derived amphotropic murine retrovirus vectors are sensitive to inactivation by human serum (Pensiero et al., 1996) . Other studies previously demonstrated that an antibody-dependent mechanism may play a predominant role for vector inactivation through ␣Gal glycosylation epitopes in the virus particles (Takeuchi et al., 1996) . However, the VSV-G-pseudotyped viral vectors used in this study were produced from TE671 cells that do not express ␣Gal. Therefore, other inactivation mechanisms must be at play.
HIV-1 vectors were much more stable in heated human serum than in unheated serum, suggesting that heating may have eliminated some destabilizing factors in the human serum. However, the heated serum still destabilized HIV-1 vectors (half-life ϭ 168 min) compared to the control incubation without human serum (halflife ϭ 321 min) at 37°C (Table 2) . It was reported earlier that HIV-1 RNA was slightly more unstable in heparinized blood than in whole EDTA blood (Bruisten et al., 1997) . We compared viral vector stability in serum without heparin to that with heparin for both human and mouse sera; a slight decrease in vector half-life was observed when heparin was used. However, the decrease was not significant and cannot account for the inactivation activity of the heated serum (data not shown).
The half-lives of both retro-and lentiviral vectors were not significantly different in heated versus unheated mouse serum. The half-life of MLV was only 2 min in the mouse sera. The SCID mouse serum study showed that the half-life of HIV-1 was not markedly changed (35 min versus 94 min), whereas the stability of MLV was significantly improved (2 min versus 156 min) ( Table 2) . Together, these data suggest that alternative factors other than complement or functional immune cell factors are still contributing to the serum inhibitory effects. Such serum sensitivity can be a significant barrier to in vivo applications of VSV-G-pseudotyped retroviral and lentiviral vectors. Understanding the destabilizing mechanisms to both retroviral and lentiviral vectors might improve vector stability and provide useful information for future gene therapy applications.
MATERIALS AND METHODS
Cells and culture conditions
TE671 (human rhabdomyosarcoma) and HeLa (human cervical carcinoma) cells were obtained from ECACC (United Kingdom) and ATCC (Rockville, MD), respectively. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Gaithersburg, MD) and 100 units/ml of penicillin-streptomycin (Gibco BRL).
Vector production and titration
A modified calcium phosphate DNA cotransfection protocol was used for the preparation of retroviral and lentiviral vectors in our laboratory (Chang et al., 1999) . Briefly, to produce lentiviral vectors, 10 g of pTV⌬EFnlacZ, 15 g of pHP⌬Nde/Ase, and 6 g of pHEF-VSVG were cotransfected with 0.5 g of a tatencoding plasmid pCEP4tat into TE671 cells (8 ϫ 10 5 ) in a six-well tissue-culture plate. To produce retroviral vectors, 10 g of pLFGEFnlacZ, 20 g of pcDNAEFgagpol, and 6 g of pHEF-VSVG were cotransfected into TE671 cells. Culture media were changed 18-24 h after DNA was added, and the virus was harvested three to four times at 12-h intervals. Virus supernatant was filtered through a 0.45-m low-protein binding filter (Millex-HV; Millipore, Bedford, MA) to remove cell debris. For pH, freeze-and-thaw, or human and mouse serum experiments, both HIV-1 and MLV were concentrated by centrifugation in a microcentrifuge at full speed (14,000 rpm) using the F45-30-11 rotor (Eppendorf, Hamburg, Germany) at 4°C for 2-3 h. The microcentrifuge protocol routinely recovers Ͼ95% of the infectious units and freeze-and-thaw does not appear to have any impact on this concentration protocol. The supernatants were stored at Ϫ80°C in aliquots until use. To determine the vector titer, two different dilutions were used to infect 6 ϫ 10 4 TE671 cells, which were plated into a 24-well plate, in a final volume of 0.2 ml containing 8 g/ml of Polybrene (Sigma, St. Louis, MO). After 3-4 h of infection, 0.5 ml of fresh media was added and, 48 h after infection, cells were fixed and stained with X-gal substrate as previously described (Chang et al., 1999) . Virus titer was determined by counting the blue nucleated cells under an inverted microscope.
Virus particle quantification under electron microscopy
MLV-and HIV-1-derived vectors were prepared by DNA cotransfection into TE671 cells as described above. The VSV-G-pseudotyped vectors were concentrated by microfuge centrifugation and the titer of each vector was determined by the ␤-galactosidase assay on TE671 cells. These virus specimens were fixed with a 2% bufferedglutaraldehyde solution, diluted if needed, and mixed at a 1:1 (v/v) ratio with a known concentration of 142-nm latex beads. The mixtures were centrifuged directly onto a copper mesh grid in a Beckman Airfuge ultracentrifuge microtube (Beckman Instruments, Fullerton, CA), negative-stained with phosphotungstic acid, and examined under a transmission electron microscope (Hitachi 7100) as previously described (Alain et al., 1987) . Particles, defective or not, with preserved retroviral morphology were counted and the results were consistent with two to three different preparations. The concentration of virus in the suspension was determined from the ratio of viral and latex particles, the ratio of viral suspension to bead suspension, and the known bead concentration.
HIV p24 ELISA
The concentration of HIV Gag p24 was determined using a commercial HIV-1 p24 Antigen Capture Assay Kit (Biological Products Laboratory, Frederick Cancer Research and Development Center, Frederick, MD).
Freeze-and-thaw preparation of viral vectors
The virus was frozen rapidly either on dry ice or in liquid nitrogen and stored at Ϫ80°C before being thawed completely at 37°C for 5 min and used to infect TE671 cells. This procedure was repeated for multiple freezeand-thaw cycles.
Temperature and pH adjustment
Viral vectors were incubated at various temperatures in a water bath: 4, 20, 37, 45, and 50°C for different lengths of time and used to infect TE671 cells. Different pH solutions were prepared as follows: 0.1 M phosphate buffer was used for the preparation of pH 5.0, 6.0, 7.0, and 0.1 M Tris-HCl buffer was used for the preparation of pH 7.0, 8.0, and 9.0. The mixture of 95 l of buffer solution with 5 l of concentrated virus was incubated at 37°C for different periods of time and used to infect TE671 cells.
Two different volumes of virus were used, 10 and 20 l, each of which was adjusted to a total 200 l of media including Polybrene.
Incubation of viral vectors in human and mouse sera
Heat treatment of serum was performed by incubating the serum at 56°C for 30 min. Virus and serum were then mixed at a 1:1 ratio and incubated at 37°C for different lengths of time. The incubation was stopped on ice and the virus/serum mixture was used to infect HeLa cells immediately using two different volumes, 5 and 8 l. At the same time, a control untreated virus sample was also used to infect HeLa cells.
